Optiscan Imaging (ASX:OIL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Optiscan Imaging (ASX:OIL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Optiscan Lodges U.S. FDA 510(k) Submission for InVue
Optiscan submits FDA 510(k) application for InVue surgical imaging device
Optiscan Lodges U.S. FDA 510(k) Submission for InForm
Optiscan lodges FDA 510(k) submission for InForm digital pathology device
Change of Director's Interest Notice
Notification of cessation of securities - OIL
Application for quotation of securities - OIL
Significant Milestone Reached in ACL Digital Pathology Study
Optiscan images 84 cases in Australian Clinical Labs digital pathology study
Change of Director's Interest Notice
Application for quotation of securities - OIL
Application for quotation of securities - OIL
Change of Director's Interest Notice
Change of Director's Interest Notice
Optiscan Initiates Head and Neck Cancer Study in the US
Optiscan launches U.S. head and neck cancer imaging study to support FDA submissions
Appendix 4G & Corporate Governance Statement
2026 Annual Report
Optiscan advances clinical-stage transition with FDA dossier submission, $17.75m capital raise, and U.S. veterinary market launch
Preliminary Final Report
Optiscan Imaging reports 53% revenue drop and increased loss in FY26, boosted by $17.75M capital raise
Quarterly Activities/Appendix 4C Cash Flow Report
Optiscan advances US FDA submissions and launches InSpecta™ in US veterinary market
Optiscan Signs New Research Agreement for Breast Study
Optiscan initiates US breast cancer imaging study with Mayo Clinic to support FDA submissions
Head and Neck Study Progressing Ahead of Schedule
Optiscan's Head and Neck Cancer Imaging Study Advances Ahead of Schedule